5-Year Outcomes with Cobimetinib plus Vemurafenib in BRAFV600 Mutation-Positive Advanced Melanoma: Extended Follow-up of the coBRIM Study.

doi:10.1158/1078-0432.CCR-21-0809

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

5-Year Outcomes with Cobimetinib plus Vemurafenib in BRAFV600 Mutation-Positive Advanced Melanoma: Extended Follow-up of the coBRIM Study.

Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Oct 2021

Ascierto Paolo A, Dréno Brigitte, Larkin James, Ribas Antoni, Liszkay Gabriella, Maio Michele, Mandalà Mario, Demidov Lev, Stroyakovskiy Daniil, Thomas Luc, de la Cruz-Merino Luis, Atkinson Victoria, Dutriaux Caroline, Garbe Claus, Hsu Jessie, Jones Surai, Li Haocheng, McKenna Edward, Voulgari Athina, McArthur Grant A

Abstract excerpt

PURPOSE: The randomized phase III coBRIM study (NCT01689519) demonstrated improved progression-free survival (PFS) and overall survival (OS) with addition of cobimetinib to vemurafenib compared with vemurafenib in patients with previously untreated BRAFV600 mutation-positive advanced melanoma. We report long-term follow-up of coBRIM, with at least 5 years since the last patient was randomized. PATIENTS AND...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Azetidines

Share to Follow-Up Studies

Share to Melanoma

Share to Piperidines

Share to Proto-Oncogene Proteins B-raf

Share to Skin Neoplasms

Share to Vemurafenib

Source

Open in PubMed Open full text

Identifiers

PMID: 34158360
DOI: 10.1158/1078-0432.CCR-21-0809
PMCID: PMC9401485

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

5-Year Outcomes with Cobimetinib plus Vemurafenib in BRAFV600 Mutation-Positive Advanced Melanoma: Extended Follow-up of the coBRIM Study.PMID 34158360Read ↗

Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial.Semantic proximity Read ↗

Extended 5-Year Follow-up Results of a Phase Ib Study (BRIM7) of Vemurafenib and Cobimetinib in BRAF-Mutant Melanoma.Semantic proximity Read ↗

Incidence, course, and management of toxicities associated with cobimetinib in combination with vemurafenib in the coBRIM study.Semantic proximity Read ↗

Long-Term Real-World Outcomes and Safety of Vemurafenib and Vemurafenib + Cobimetinib Therapy in Patients with BRAF-Mutated Melanoma.Semantic proximity Read ↗

Combined vemurafenib and cobimetinib in BRAF-mutated melanoma.Semantic proximity Read ↗

Cobimetinib.Semantic proximity Read ↗

coBRIM: a phase 3, double-blind, placebo-controlled study of vemurafenib versus vemurafenib + cobimetinib in previously untreated BRAFV600 mutation–positive patients with unresectable locally advanced or metastatic melanoma (NCT01689519)Semantic proximity Read ↗

Cobimetinib Plus Vemurafenib: A Review in BRAF (V600) Mutation-Positive Unresectable or Metastatic Melanoma.Semantic proximity Read ↗

The safety and efficacy of cobimetinib for the treatment of BRAF V600E or V600K melanoma.Semantic proximity Read ↗

Cobimetinib: inhibiting MEK1/2 in BRAF V600-mutant melanoma.Semantic proximity Read ↗

Combination of vemurafenib and cobimetinib in patients with advanced BRAF(V600)-mutated melanoma: a phase 1b study.Semantic proximity Read ↗

Survival in adult patients with BRAFV600 mutation-positive advanced melanoma: a noninterventional ambispective study of patients with cobimetinib combined with vemurafenib during the French early access program: MELANIS study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.